Predictive factors for erectile dysfunction in men with prostate cancer after brachytherapy: Is dose to the penile bulb important?

MacDonald, Alan G.; Keyes, Mira; Kruk, Alexandra; Duncan, Graeme; Moravan, Veronika; Morris, William

doi:10.1016/j.ijrobp.2004.12.056

Cited by 68 publications

(53 citation statements)

References 26 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…In their report, the authors found that if 70% of the penile bulb exceeded 70 Gy, the likelihood of developing ED increased significantly, whereas at doses less than 40 Gy, the risk was significantly lower. Regarding ED after brachytherapy, Macdonald et al 45 reported no correlation between penile bulb dose and risk of ED.…”

Section: Discussionmentioning

confidence: 99%

An analysis of erectile function after intensity modulated radiation therapy for localized prostate carcinoma

Brown

Brooks

Albert

et al. 2006

Prostate Cancer Prostatic Dis

View full text Add to dashboard Cite

Radiation therapy for prostate cancer can cause erectile dysfunction (ED). Intensity Modulated Radiation Therapy (IMRT) can reduce the amount of radiation to surrounding tissues associated with ED. We characterize the incidence of and factors associated with ED in prostate cancer patients after IMRT at the National Naval Medical Center (NNMC). Patients potent by definition of the Sexual Health Inventory for Men (SHIM) before treatment completed the specific erectile questions of the SHIM after IMRT. Statistical analyses were performed to examine the relationships between several factors and ED. Thirty-two of 45 patients with mean age of 68.2 years (50-86 years) completed the SHIM. The median follow-up was 36.8 months (16-63.6 months) as defined by the time from completion of therapy to reassessment with the SHIM. Eight of 32 patients (25%) had no post-treatment ED (SHIM score 22-25), three of 32 (9%) had mild post-treatment ED (SHIM score 17-21), five of 32 (16%) had mild to moderate ED (SHIM score 12-16), five of 32 (16%) had moderate ED (SHIM score 8-11) and 11 of 32 (34%) had severe post-treatment ED (SHIM scoreo8). Posttreatment potency was significantly associated with the pre-treatment SHIM score (P ¼ 0.001) and history of hypertension (P ¼ 0.03). The mean radiation dose to the penile bulb and volume of penile bulb treated were not associated with post-treatment potency (P ¼ 0.38, 0.76, respectively). IMRT maintains potency in the majority of patients. This analysis compares favorably in preserving erectile function to previously reported series using conventional external beam radiation therapy techniques. The dose of radiation received by the penile bulb and volume of penile bulb were not associated with post-treatment ED in this analysis.

show abstract

Section: Discussionmentioning

confidence: 99%

An analysis of erectile function after intensity modulated radiation therapy for localized prostate carcinoma

Brown

Brooks

Albert

et al. 2006

Prostate Cancer Prostatic Dis

View full text Add to dashboard Cite

show abstract

“…However, this template restricts the possible insertion locations and directions, which can make puncturing obstructions such as penile bulb unavoidable. Puncturing healthy tissues results in trauma related sideeffects such as tissue swelling; urinary infections & incontinence; and impotence [20, part 7], [21]. A freehand approach for needle insertion based on trans-rectal ultrasound guidance was developed [19].…”

Section: Background and Related Workmentioning

confidence: 99%

Exact reachability analysis for planning skew-line needle arrangements for automated brachytherapy

Garg

Siauw

Yang

et al. 2014

2014 IEEE International Conference on Automation Science and Engineering (CASE)

View full text Add to dashboard Cite

Abstract-When planning skew-line needle arrangements for automated brachytherapy, one objective is to identify a set of candidate needles that enter from a specified entry region, avoid specified organs-at-risk and sufficiently cover the target (tumor) volume. Existing methods use uniform or random sampling to generate a set of candidate needles, which may not adequately cover the target volume. In this paper we present an exact reachability analysis that can be used to guide the selection of candidate needles and to identify which subset of the target volume may not be reachable. Assuming linear needles, convex polyhedral representations of entry zone, organs-at-risk and target volume, we give an exact polynomial time algorithm for checking existence and calculation of the non-reachable set in the target volume. We perform experiments using patient data from 18 brachytherapy cases and found that 11 cases had nonempty occluded volume inside the target ranging from 0.01% to 4.3% of target volume. We also report a sensitivity study showing the change in the occluded volume with dilation of the avoidance volume and entry zone.

show abstract

“…28,[39][40][41] A recent British Columbia study of >1400 patients showed that the 8-year potency preservation rate is 60% to 80% in men age <60, 55% to 60% in those between 60 and 69 years old and 20% to 30% in those over 70 years old. Loss of erectile function is most prominent within the first 3 years after the treatment, with little additional deterioration in potency rates at 5 and 8 years after brachytherapy.…”

Section: Ldr Side Effectsmentioning

confidence: 99%

Canadian Prostate Brachytherapy in 2012

Keyes

Crook

Morris

et al. 2013

CUAJ

Self Cite

View full text Add to dashboard Cite

Prostate brachytherapy can be used as a monotherapy for low-and intermediate-risk patients or in combination with external beam radiation therapy (EBRT) as a form of dose escalation for selected intermediate-and high-risk patients. Prostate brachytherapy with either permanent implants (low dose rate [LDR]) or temporary implants (high dose rate [HDR]) is emerging as the most effective radiation treatment for prostate cancer. Several large Canadian brachytherapy programs were established in the mid-to late-1990s. Prostate brachytherapy is offered in British Columbia, Alberta, Manitoba, Ontario, Quebec and New Brunswick. We anticipate the need for brachytherapy services in Canada will significantly increase in the near future. In this review, we summarize brachytherapy programs across Canada, contemporary eligibility criteria for the procedure, toxicity and prostate-specific antigen recurrence free survival (PRFS), as published from Canadian institutions for both LDR and HDR brachytherapy.

show abstract

Predictive factors for erectile dysfunction in men with prostate cancer after brachytherapy: Is dose to the penile bulb important?

Cited by 68 publications

References 26 publications

An analysis of erectile function after intensity modulated radiation therapy for localized prostate carcinoma

An analysis of erectile function after intensity modulated radiation therapy for localized prostate carcinoma

Exact reachability analysis for planning skew-line needle arrangements for automated brachytherapy

Canadian Prostate Brachytherapy in 2012

Contact Info

Product

Resources

About